These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Goal-Oriented Monitoring of Cyclosporine Is Effective for Graft-versus-Host Disease Prevention after Hematopoietic Stem Cell Transplantation in Sickle Cell Disease and Thalassemia Major. Gauthier A; Bleyzac N; Garnier N; Kebaili K; Joly P; Goutagny MP; Mollet I; Goutelle S; Renard C; Bertrand Y Biol Blood Marrow Transplant; 2020 Dec; 26(12):2285-2291. PubMed ID: 32007639 [TBL] [Abstract][Full Text] [Related]
9. Addition of ruxolitinib in Graft-versus-Host disease prophylaxis for pediatric β-Thalassemia major patients after allogeneic stem cell transplantation: A retrospective cohort study. Hong X; Chen Y; Lu J; Lu Q Pediatr Transplant; 2023 Mar; 27(2):e14466. PubMed ID: 36597217 [TBL] [Abstract][Full Text] [Related]
10. Vitamin D has no impact on outcomes after HSCT in children-A retrospective study. Bajwa RPS; Taylor K; Hoyt A; Kamboj MK; Stanek J; Mahadeo KM; Alsaedi H; Abdel-Azim H; O'Kane S; Martin PL; Stafford LA; Dvorak CC Pediatr Transplant; 2021 Jun; 25(4):e14008. PubMed ID: 33734544 [TBL] [Abstract][Full Text] [Related]
11. Transplant Outcomes in Beta-Thalassemia Major Patients Receiving Combined Granulocyte Colony-Stimulating Factor-Primed Bone Marrow and Cord Blood Graft Compared to Granulocyte Colony-Stimulating Factor-Primed Bone Marrow Alone. Wen J; Haque Q; Pei F; Chen L; Ruan Y; Liu X; He Y; Feng X; Li C; Wu X Acta Haematol; 2018; 140(1):20-29. PubMed ID: 30071526 [TBL] [Abstract][Full Text] [Related]
12. Association between Vitamin D and Risk for Early and Late Post-Transplant Complications. Bhandari R; Malvar J; Sacapano A; Aguayo-Hiraldo P; Jodele S; Orgel E Biol Blood Marrow Transplant; 2020 Feb; 26(2):343-350. PubMed ID: 31654787 [TBL] [Abstract][Full Text] [Related]
13. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843 [TBL] [Abstract][Full Text] [Related]
14. Vitamin D Deficiency and Survival in Children after Hematopoietic Stem Cell Transplant. Wallace G; Jodele S; Howell J; Myers KC; Teusink A; Zhao X; Setchell K; Holtzapfel C; Lane A; Taggart C; Laskin BL; Davies SM Biol Blood Marrow Transplant; 2015 Sep; 21(9):1627-31. PubMed ID: 26093045 [TBL] [Abstract][Full Text] [Related]
15. Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen. Sun L; Wang N; Chen Y; Tang L; Xing C; Lu N; Shi Y; Ma Y; Lin F; Yu K; Feng J Biol Blood Marrow Transplant; 2019 Aug; 25(8):1592-1596. PubMed ID: 30951841 [TBL] [Abstract][Full Text] [Related]
16. Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience. Yesilipek MA; Uygun V; Kupesiz A; Karasu G; Ozturk G; Ertem M; Şaşmaz İ; Daloğlu H; Güler E; Hazar V; Fisgin T; Sezgin G; Kansoy S; Kuşkonmaz B; Akıncı B; Özbek N; İnce EÜ; Öztürkmen S; Küpesiz FT; Yalçın K; Anak S; Bozkurt C; Karakükçü M; Küpeli S; Albayrak D; Öniz H; Aksoylar S; Okur FV; Albayrak C; Yenigürbüz FD; Bozkaya İO; İleri T; Gürsel O; Karagün BŞ; Kintrup GT; Çelen S; Elli M; Aksoy BA; Yılmaz E; Tanyeli A; Akyol ŞT; Siviş ZÖ; Özek G; Uçkan D; Kartal İ; Atay D; Akyay A; Bilir ÖA; Çakmaklı HF; Kürekçi E; Malbora B; Akbayram S; Demir HA; Kılıç SÇ; Güneş AM; Zengin E; Özmen S; Antmen AB Bone Marrow Transplant; 2022 May; 57(5):760-767. PubMed ID: 35210564 [TBL] [Abstract][Full Text] [Related]
17. Gut microbiota trajectory in β-thalassemia major children who underwent allogeneic hematopoietic stem cell transplantation. Luo H; Liu T; Qu Y; Kuang C; Xiao M; Sun J; Chen H; Wu J; Liu X; Jiang H Transpl Infect Dis; 2023 Oct; 25(5):e14111. PubMed ID: 37615262 [TBL] [Abstract][Full Text] [Related]
18. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India. Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007 [TBL] [Abstract][Full Text] [Related]
19. Variability of contribution of 1,25 (OH) Kamel AM; Radwan ER; Zeidan A; Zaky A; Ibrahim A; Refaat A; Abdelfattah R; Abdelfattah M Clin Nutr ESPEN; 2023 Dec; 58():355-361. PubMed ID: 38057027 [TBL] [Abstract][Full Text] [Related]
20. Effect of serum panel reactive antibodies on allogeneic hematopoietic stem cell transplantation in pediatric thalassemia patients: A single-center experience. Malbora B; Sarbay H; Dogusan Z; Atay AA Pediatr Transplant; 2024 Feb; 28(1):e14648. PubMed ID: 38063291 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]